Equibles does not estimate personal net worth.
Get an email with a short summary when Madrigal Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.
Get MDGL alertsWilliam Sibold is recorded as CEO at Madrigal Pharmaceuticals, Inc. (MDGL). William Sibold has spoken on 3 earnings calls and 1 other investor event across 1 company, most recently for Madrigal Pharmaceuticals, Inc. on June 10, 2026. Madrigal Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Madrigal Pharmaceuticals, Inc. includes Bill Sibold (CEO and Board Member), Julian C. Baker (Chairman and Board Member), Mardi Dier (CFO) and 7 others.
“It's always great to be at the conference. And, you know, it's always good when you have a conference like this to look back what's happened since the last time we were here.”
“Today I'll provide an update on the ResDiffer launch where we ended our first full year on the market at nearly $1 billion in net sales and solidified ResDifera as the foundational therapy in MASH.”
“We have delivered another excellent quarter as we continue to execute on our strategic priorities. We're maximizing the value of Rezdiffra and building our pipeline, which sets us up for continued value creation.”
“I mean, look, I guess we'll find out more this year about if anyone manages to show the same impressive efficacy results that we've achieved by hitting on both primary endpoints.”
Biotechnology · Healthcare
CEO
